Abstracts tagged "Sjogren’s syndrome and abatacept"

Abstract Number: 1907 • 2019 ACR/ARP Annual Meeting
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Jacques-Eric Gottenberg¹, Sumanta Mukherjee ², Marleen Nys ³, Robert Wong ⁴, Hendrika Bootsma ⁵ and Neelanjana Ray ⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁴Bristol-Myers Squibb, Princeton, ⁵University of Groningen, Groningen, Netherlands
Background/Purpose: Chemokine (C-X-C motif) ligand 13 (CXCL13), produced by follicular helper T (Tfh) cells, plays a pivotal role in B-cell homing and activation in germinal…
Abstract Number: 1124 • 2015 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Levels Are Increased in B Cells from Patients with Primary Sjögren’s Syndrome
Odilia B.J. Corneth¹, Gwenny Verstappen², Marjolein de Bruijn¹, Erlin A. Haacke³, Arjan Vissink⁴, Hendrika Bootsma⁵, Frans G.M. Kroese² and Rudi W. Hendriks¹, ¹Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Upon B cell receptor stimulation, B cells increase protein expression levels of the key downstream signaling molecule Bruton’s tyrosine kinase (BTK). BTK-transgenic mice that…
Abstract Number: 2553 • 2012 ACR/ARHP Annual Meeting
Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren’s Syndrome
Sabine Adler¹, Meike Koerner², Frauke Foerger³, Marco-Domenico Caversaccio⁴ and Peter M. Villiger⁵, ¹Rheumatology, University Hospital Bern, Bern, Switzerland, ²Pathology, University Hospital Bern, Bern, Switzerland, ³Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁴Ear Nose and Throat, University Hospital Bern, Inselspital, Bern, Switzerland, ⁵Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: To prospectively evaluate histopathologic, blood and clinical responses to abatacept treatment in patients with primary Sjögren’s syndrome (pSS). Methods: Blood, saliva and minor salivary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].